Claude for Pharmaceuticals

GxP validation is per-deployment, not per-vendor. Our engineering practice supports GxP-validated deployments with computer-system-validation cycles, validated-environment configurations, and 21 CFR Part 11-compliant audit trails. The validation itself is jointly executed with the client's quality and regulatory teams; we provide the engineering artefacts, they own the validation outcome.

Claude can support regulatory-submission preparation — drafting CMC sections, clinical-summary modules, and regulator correspondence — under regulatory-affairs review. The submission itself is regulatory-affairs-authored and submitted; Claude reduces the human effort of producing the artefacts. We have shipped this pattern with regulatory teams maintaining higher submission cadence than they could sustain manually.

GVP imposes specific obligations on adverse-event handling — case processing, signal detection, periodic safety reporting. Our pharmacovigilance Claude deployments support case-narrative processing and signal-threshold pre-classification with the pharmacovigilance team retaining decision authority. The audit trail is the operative quality artefact; we generate it by default.

Direct unattended write-back to validated systems is rare and high-risk. Our typical pattern is Claude drafts content, system-of-record write-back happens through validated workflows with human review. Some operational systems (CTMS, eTMF) allow drafted-content uploads with audit trail; the deployment architecture identifies the right boundary per system.

Clinical-trial subject data (especially in EU multi-country trials) is high-sensitivity GDPR territory. Our deployments integrate purpose-limitation, data-minimisation, lawful-basis discipline (typically explicit consent for special-category data), and cross-border-transfer mechanisms. AWS Bedrock and Azure EU regions are common deployment patterns for data-residency.

RWE Claude deployments process structured and unstructured patient-record data for HTA, post-marketing-surveillance, and outcomes-research applications. Privacy controls are paramount — anonymisation discipline, k-anonymity verification, and re-identification-risk modelling are part of the architecture-phase work.

Our engineers have engineered software in oncology, immunology, CNS, rare-disease, and primary-care therapeutic areas. Therapeutic-area expertise informs the prompt design and the eval-set construction; we do not market generic 'pharma' deployments without therapeutic-area calibration.

16–28 weeks for a GxP-validated deployment. Validation cycles are the long pole — engineering pace is comparable to other regulated industries, but the validation discipline lengthens the calendar. Non-GxP deployments (medical-affairs information requests, internal knowledge-base RAG) run faster — 10–16 weeks.